Viz.ai has announced it will use its Viz Recruit platform to optimise patient enrolment for the National Institutes of Health (NIH)-funded Pulmonary embolism—thrombus removal with catheter-directed thrombolysis (PE-TRACT) clinical trial.
The company claims that PE-TRACT will be the most rigorous randomised controlled clinical trial to date of catheter-directed therapy for PE, with plans to enrol 500 patients across 30–50 sites.
The PE-TRACT trial is designed to address whether catheter therapy should be routinely used to treat intermediate-risk PE versus anticoagulants alone.
“The PE-TRACT trial will offer a deeper knowledge of PE by providing a comprehensive comparison of catheter-directed therapy plus anticoagulation to anticoagulation alone,” said Akhilesh Sista (Weill Cornell Medical College, New York, USA), principal investigator of the PE-TRACT trial. “PE-TRACT will provide valuable insights to patients and providers regarding which approach best maintains cardiopulmonary health in the year following PE. Viz.ai’s Recruit tool has the potential to efficiently identify potential participants and help this important trial complete enrolment on time.”
Participating research institutions in the PE-TRACT trial will use Viz Recruit to find, screen, and enrol clinical trial candidates. Viz Recruit, an artificial intelligence (AI)-powered clinical trial enrolment platform, automates the identification and triage of eligible candidates for pre-trial review, while reducing the burden on the research team. Using Viz Recruit, sites will be able to automatically screen patients based on PE and high right ventricular to left ventricular diameter (RV/LV) ratio. The cloud-based technology helps to broaden the recruitment funnel in both size and diversity and streamlines the trial enrolment workflow. To date, Viz Recruit has been used to screen nearly 300,000 patients and identify over 14,000 clinical trial candidates across 100 healthcare facilities, a press release reports.